Aurinia settles Teva patent litigation; generic voclosporin launch no earlier than Dec 7, 2036

Aurinia Pharmaceuticals Inc.

Settlement with Teva resolves generic patent litigation over Teva's ANDA for 7.9 mg voclosporin oral capsules.
Teva stipulates U.S. Patent Nos. 10,286,036 and 11,622,991 valid, enforceable, and infringed; patents expire December 2037.
Teva may launch generic voclosporin no earlier than Dec 7, 2036, subject to FDA approval and certain defined contingencies.
Aurinia's patent actions continue against DifGen, Dr. Reddy's, Galenicum, Hikma, Lotus, Sandoz, and Zydus in District of New Jersey.

Featured in Daily 8-K Digest

Selected #6 for 2026-08-19. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.